麻黄厚朴汤辅助治疗小儿咳嗽变异性哮喘寒饮伏肺证59例临床观察  

Clinical observation of Mahuang Houpu Tang(麻黄厚朴汤)as an adjunctive treatment for 59 cases of pediatric cough variant asthma of cold-fluid retention in the lung type

作　　者：罗延昭 何春风[1] LUO Yanzhao;HE Chunfeng(Department of Pediatrics,Lishui People's Hospital,Lishui,Zhejiang,323300,China)

机构地区：[1]丽水市人民医院儿科,浙江丽水323300

出　　处：《中医儿科杂志》2025年第2期56-60,共5页Journal of Pediatrics of Traditional Chinese Medicine

摘　　要：目的观察麻黄厚朴汤辅助治疗小儿咳嗽变异性哮喘(CVA)寒饮伏肺证的临床疗效及对肺功能和炎症因子的影响。方法选取2021年1月至2022年12月丽水市人民医院儿科收治的118例CVA寒饮伏肺证患儿,按照随机数字表法分为对照组和治疗组,各59例。对照组给予常规西药治疗,治疗组在对照组治疗方法的基础上联合麻黄厚朴汤加味。2组均连续治疗1周后统计临床疗效。结果对照组总有效率为83.05%(49/59),治疗组为96.61%(57/59),2组比较,差异有统计学意义(P<0.05)。治疗前2组中医证候评分比较,差异无统计学意义(P>0.05),具有可比性;治疗后2组中医证候评分均显著下降,与同组治疗前比较,差异有统计学意义(P<0.05),且治疗组各项评分下降更显著(P<0.05)。治疗前2组用力肺活量(FVC)、第1秒用力呼气量(FEV_(1))、FEV_(1)/FVC水平比较,差异无统计学意义(P>0.05),具有可比性;治疗后2组FVC、FEV_(1)、FEV_(1)/FVC水平均显著升高,与同组治疗前比较,差异有统计学意义(P<0.05),且治疗组上述指标升高更显著(P<0.05)。治疗前2组血清炎症因子超敏C反应蛋白(hs-CRP)、白细胞介素-17(IL-17)、白细胞介素-23(IL-23)水平比较,差异无统计学意义(P>0.05),具有可比性;治疗后2组上述指标水平均显著下降,与同组治疗前比较,差异有统计学意义(P<0.05),且治疗组上述指标下降更显著(P<0.05)。对照组不良反应发生率为15.25%(9/59),治疗组为3.38%(2/59),2组比较,差异有统计学意义(P<0.05)。结论麻黄厚朴汤辅助治疗小儿CVA寒饮伏肺证,能明显改善患儿的临床症状和肺功能,降低血清炎症因子水平,安全性高,值得临床推广应用。ObjectiveTo observe the clinical efficacy of Mahuang Houpu Tang(麻黄厚朴汤)as an adjunctive treatment for pediatric cough variant asthma(CVA)of cold-fluid retention in the lung type and its effects on lung function and inflammatory factors.Methods lung type,admitted to the Department of Pediatrics at Lishui People's Hospital from January 2021 to December2022,were selected and randomly divided into a control group and a treatment group,with 59 cases in each group.The control group received conventional Western medicine treatment,while the treatment group received Mahuang Houpu Tang in addition to the control group's treatment.Both groups were treated for one week,after which clinical efficacy was evaluated.ResultsThe total effective rate was 83.05%(49/59)in the control group and 96.61%(57/59)in the treatment group,with a statistically significant difference between the two groups(P<0.05).Before treatment,there was no significant difference in TCM syndrome scores between the two groups(P>0.05),indicating comparability.After treatment,both groups showed significant reductions in TCM syndrome scores compared to pretreatment(P<0.05),with the treatment group demonstrating more pronounced reductions(P<0.05).Before treatment,there were no significant differences in forced vital capacity(FVC),forced expiratory volume in one second(FEV_(1)),or FEV_(1)/FVC levels between the two groups(P>0.05),indicating comparability.After treatment,both groups showed significant improvements in FVC,FEV_(1),and FEV_(1)/FVC levels compared to pre-treatment(P<0.05),with the treatment group showing more significant improvements(P<0.05).Before treatment,there were no significant differences in inflammatory factors,including high-sensitivity C-reactive protein(hs-CRP),interleukin-17(IL-17),and interleukin-23(IL-23)levels,between the two groups(P>0.05),indicating comparability.After treatment,both groups showed significant reductions in these inflammatory factors compared to pre-treatment(P<0.05),with the treatment group demonstrating more

关 键 词：咳嗽变异性哮喘 小儿 寒饮伏肺证 麻黄厚朴汤 临床观察 

分 类 号：R256.12[医药卫生—中医内科学]